Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components

• Published in: Frontiers in immunology Vol. 13; p. 856657
• Main Authors: Busà, Rosalia, Sorrentino, Maria Concetta, Russelli, Giovanna, Amico, Giandomenico, Miceli, Vitale, Miele, Monica, Di Bella, Mariangela, Timoneri, Francesca, Gallo, Alessia, Zito, Giovanni, Di Carlo, Daniele, Conaldi, Pier Giulio, Bulati, Matteo
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 24.03.2022
• Subjects: B cells; BNT162 Vaccine; BNT162b2; booster dose; COVID-19 - prevention & control; COVID-19 Vaccines; Humans; Immunity, Cellular; Immunology; mRNA vaccine; mRNA Vaccines; RNA, Messenger - genetics; SARS-CoV-2; T cells; T-Lymphocytes; Vaccines, Synthetic; SARS-CoV-2; BNT162b2; B cells; T cells; booster dose; mRNA vaccine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynam...